KalVista Pharmaceuticals Profit Margin

The latest profit margin for KALV is -101.47% as of March 2026. That compares with -14582.92% in the prior-year period — up 99.3% year over year. That is below the Healthcare sector average of 19.13%. Investors often review this figure alongside KalVista Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, KALV's profit margin moved from -14582.92% to -101.47% — a 99.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in KalVista Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, KALV currently prints -101.47% for profit margin, while the sector average sits near 19.13%. That is roughly 630.4% below the sector mean. Large gaps often invite a closer look at KalVista Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively KalVista Pharmaceuticals converts resources into returns. At -101.47%, KALV may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -14582.92% in the prior-year period — up 99.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting KALV's profit margin (-101.47%), review year-over-year change from -14582.92%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.